Table 3.
Training set and Test set variability analysis.
| Variable | Total (N = 808) | Train set (N = 565) | Test set (N = 243) | P |
|---|---|---|---|---|
| Age | 65.00 [59.00, 70.00] | 65.00 [59.00, 70.00] | 65.00 [58.00, 70.00] | 0.727 |
| BMI | 21.50 [19.7, 23.70] | 21.50 [19.60, 23.70] | 21.60 [20.00, 23.60] | 0.497 |
| Chemotherapy cycles | 5.00 [2.00, 8.00] | 5.00 [2.00, 8.00] | 5.00 [2.00, 9.00] | 0.737 |
| Hospitalizations | 7.00[4.00, 12.00] | 7.00 [4.00, 12.00] | 7.00 [3.00, 12.00] | 0.927 |
| WBC | 6.90 [5.49, 9.17] | 6.82 [5.49, 8.94] | 7.37 [5.47, 9.89] | 0.075 |
| RBC | 3.77 [3.30, 4.15] | 3.77 [3.33, 4.14] | 3.76 [3.29, 4.19] | 0.644 |
| HGB | 112.00 [99.90, 125.00] | 112.00 [99.30, 124.00] | 112.00 [100.00, 125.00] | 0.810 |
| PLT | 209.00 [160.00, 258.00] | 210.00 [159.00, 262.00] | 209.00 [163.00, 243.00] | 0.411 |
| NEUT | 72.10 [64.30, 79.20] | 71.60 [63.60, 78.90] | 73.30 [66.10, 80.10] | 0.073 |
| LYM | 17.30 [12.00, 23.30] | 17.50 [12.20, 23.70] | 16.80 [11.40, 23.00] | 0.249 |
| MONO | 7.30 [5.40, 9.48] | 7.23 [5.50, 9.50] | 7.40 [5.05, 9.30] | 0.456 |
| NLR | 4.38 [2.83, 7.09] | 4.27 [2.73, 6.89] | 4.46 [2.97, 7.60] | 0.137 |
| NMR | 10.10 [6.79, 14.03] | 10.20 [7.00, 14.40] | 10.00 [7.46, 14.50] | 0.375 |
| NPR | 0.35 [0.27, 0.43] | 0.34 [0.27, 0.43] | 0.36 [0.28, 0.44] | 0.108 |
| IBIL | 7.30 [5.70, 9.39] | 7.24 [5.79, 9.30] | 7.40 [5.60, 9.72] | 0.700 |
| ALT | 18.00 [12.70, 26.30] | 18.20 [12.40, 27.00] | 17.40 [13.30, 24.30] | 0.853 |
| AST | 23.40 [19.40, 29.40] | 23.40 [19.30, 29.00] | 23.50 [19.70, 29.70] | 0.805 |
| TBIL | 9.89 [7.63, 12.60] | 9.80 [7.70, 12.40] | 9.90 [7.50, 12.80] | 0.955 |
| DBIL | 2.40 [1.59, 3.40] | 2.44 [1.60, 3.40] | 2.30 [1.48, 3.39] | 0.467 |
| TP | 66.80 [62.30, 69.90] | 66.70 [62.20, 70.00] | 67.20 [62.40, 69.80] | 0.939 |
| ALB | 40.00 [36.50, 42.50] | 39.90 [36.70, 42.40] | 40.20 [36.30, 42.70] | 0.931 |
| GLB | 26.30 [23.50, 29.40] | 26.30 [23.70, 29.10] | 26.40 [22.80, 30.00] | 0.967 |
| A/G | 1.54 [1.31, 1.75] | 1.54 [1.32, 1.75] | 1.55 [1.26, 1.77] | 0.975 |
| Urea | 5.89 [4.74, 7.56] | 5.92 [4.69, 7.63] | 5.84 [4.89, 7.32] | 0.540 |
| CREA | 78.80 [66.00, 92.30] | 78.50 [66.60, 92.20] | 79.80 [64.00, 92.90] | 0.889 |
| UA | 330.00 [278.00, 394.00] | 330.00 [279.00, 394.00] | 330.00 [277.00, 395.00] | 0.951 |
| CEA | 3.69 [2.11, 9.74] | 3.69 [2.14, 9.87] | 3.66 [2.03, 8.29] | 0.447 |
| Gender, n (%) | 0.298 | |||
| Male | 683 (84.50%) | 483 (85.50%) | 200 (82.30%) | |
| Female | 125 (15.50%) | 82 (14.50%) | 43 (17.70%) | |
| Drink, n (%) | 0.385 | |||
| No | 683 (84.50%) | 473 (83.70%) | 210 (86.40%) | |
| Yes | 125 (15.50%) | 92 (16.30%) | 33 (13.60%) | |
| Smoke, n (%) | 0.087 | |||
| No | 518 (64.10%) | 351 (62.10%) | 167 (68.70%) | |
| Yes | 290 (35.90%) | 214 (37.90%) | 76 (31.30%) | |
| Diabetes, n (%) | 0.864 | |||
| No | 731 (90.50%) | 510 (90.30%) | 221 (90.90%) | |
| Yes | 77 (9.50%) | 55 (9.70%) | 22 (9.10%) | |
| Hypertension, n (%) | 0.371 | |||
| No | 636 (78.70%) | 450 (79.60%) | 186 (76.50%) | |
| Yes | 172 (21.30%) | 115 (20.40%) | 57 (23.50%) | |
| CHD, n (%) | 0.226 | |||
| No | 759 (93.90%) | 535 (94.70%) | 224 (92.20%) | |
| Yes | 49 (6.10%) | 30 (5.30%) | 19 (7.80%) | |
| Stage, n (%) | 0.779 | |||
| Stage I | 29 (3.60%) | 20 (3.50%) | 9 (3.70%) | |
| Stage II | 96 (11.90%) | 71 (12.60%) | 25 (10.30%) | |
| Stage III | 330 (40.80%) | 232 (41.10%) | 98 (40.30%) | |
| Stage IV | 353 (43.70%) | 242 (42.80%) | 111 (45.70%) | |
| Histology, n (%) | 0.537 | |||
| Adenocarcinoma | 327 (40.50%) | 221 (39.10%) | 106 (43.60%) | |
| Squamous | 333 (41.20%) | 241 (42.70%) | 92 (37.90%) | |
| SCLC | 135 (16.70%) | 93 (16.50%) | 42 (17.30%) | |
| Other lung cancers | 13 (1.60%) | 10 (1.80%) | 3 (1.20%) | |
| PE | 0.237 | |||
| No | 608 (75.20%) | 418 (74.00%) | 190 (78.20%) | |
| Yes | 200 (24.80%) | 147 (26.00%) | 53 (21.80%) |